Zacks Investment Research lowered shares of KemPharm (NASDAQ:KMPH) from a buy rating to a hold rating in a report issued on Wednesday.
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
Separately, ValuEngine upgraded shares of KemPharm from a strong sell rating to a sell rating in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $8.15.
KemPharm (NASDAQ:KMPH) remained flat at $$5.00 during midday trading on Wednesday. 76,446 shares of the company were exchanged, compared to its average volume of 52,272. KemPharm has a twelve month low of $2.45 and a twelve month high of $5.40. The company has a debt-to-equity ratio of -1.92, a current ratio of 7.56 and a quick ratio of 7.56.
In other news, EVP Daniel L. Cohen acquired 7,500 shares of the company’s stock in a transaction dated Monday, November 27th. The shares were bought at an average price of $3.79 per share, for a total transaction of $28,425.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 22.80% of the company’s stock.
An institutional investor recently raised its position in KemPharm stock. Alyeska Investment Group L.P. grew its position in shares of KemPharm, Inc. (NASDAQ:KMPH) by 1.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 992,338 shares of the specialty pharmaceutical company’s stock after purchasing an additional 17,721 shares during the period. Alyeska Investment Group L.P. owned approximately 6.77% of KemPharm worth $3,672,000 as of its most recent SEC filing. Institutional investors and hedge funds own 36.04% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Lowers KemPharm (KMPH) to Hold” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://transcriptdaily.com/2018/01/14/zacks-investment-research-lowers-kempharm-kmph-to-hold.html.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.